Chir-258

Neoplasms

Novartis PharmaceuticalsPhase 2/3Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 65/ 100

Competitive context

119 Active assets in the Neoplasms cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE Hellenic Society of Hematology	Phase 3	BB
Feladilimab GlaxoSmithKline	Phase 2	BB
Carboplatin Bristol-Myers Squibb	Phase 3	BB
Cetuximab Mirati Therapeutics Inc.	Phase 4	B
PREDNISONE TABLETS The First Affiliated Hospital of Soochow University	Phase 3	B

View all 50 →

Same molecule, other indications

Chir-258 is also rated in:

Stage III Pancreatic CancerDormant

CCC

Indicative ·

54 / 100

Breast CancerDormant

CCC

Indicative ·

52 / 100

Adult Giant Cell GlioblastomaDormant

CCC

Indicative ·

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.